Literature DB >> 3468102

The comparative pharmacokinetics of five quinolones.

R Wise, D Lister, C A McNulty, D Griggs, J M Andrews.   

Abstract

The pharmacokinetics and tissue penetration of five quinolones were studied in volunteers. The compounds were norfloxacin (400 mg po), enoxacin (400 mg iv and 600 mg po), ciprofloxacin (100 mg iv and 500 mg po), ofloxacin (600 mg po) and pefloxacin (400 mg iv). Of the oral agents studied ofloxacin and ciprofloxacin were the most rapidly absorbed (Tmax = 1.2 h) and enoxacin the least (Tmax = 1.9 h). The serum levels attained were highest in the case of ofloxacin (after allowing for the higher dose administered). The serum half-lives were norfloxacin 3.75 h, ciprofloxacin 3.9 h (po), 4.0 h (iv), ofloxacin 7.0 h, enoxacin 6.2 h (po), 5.1 h (iv) and pefloxacin 10.5 h. All agents penetrated blister fluid readily. The 24 h urine recovery was 62% for oral enoxacin, 46.4% for iv enoxacin (plus 12.2% for oxo-enoxacin), 27% for norfloxacin, 30.6% for oral ciprofloxacin, 75.7% for iv ciprofloxacin, 73% for ofloxacin and 4.9% for pefloxacin (plus 9.2% for the norfloxacin metabolite and 17.8% for pefloxacin N-oxide).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3468102     DOI: 10.1093/jac/18.supplement_d.71

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  35 in total

Review 1.  Clinical role of protein binding of quinolones.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Use of fluoroquinolone antimicrobial agents by cardiovascular and cardiopulmonary surgeons.

Authors:  H C Neu
Journal:  Tex Heart Inst J       Date:  1990

3.  Differential intracellular efficacies of ciprofloxacin and cefixime against Neisseria gonorrhoeae in human fallopian tube organ culture.

Authors:  J P Phanucharas; G L Gorby
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; G Cornaglia
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 5.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

6.  [Multi-step increase in resistance of Neisseria gonorrhoeae isolates after repeated in-vitro subinhibitory concentrations of second-generation quinolones].

Authors:  H C Korting; A Lukacs
Journal:  Infection       Date:  1989       Impact factor: 3.553

7.  Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses.

Authors:  J Kavi; J Stone; J M Andrews; J P Ashby; R Wise
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-02       Impact factor: 3.267

8.  A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; Y A Portnoy; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; S H Zinner; G Cornaglia; Y A Portnoy
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model.

Authors:  B Fantin; J Leggett; S Ebert; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.